Predicting left atrial thrombi in atrial fibrillation

Waldemar E. Wysokinski, Naser Ammash, Folakemi Sobande, Henna Kalsi, David Hodge, Robert D. McBane

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Background: The aim of the study was to determine whether CHADS2 score is predictive of left atrial appendage thrombus (LAAT) in nonvalvular atrial fibrillation (AF). Strategies for effective stroke prevention in AF require tools capable of identifying those patients at greatest risk for embolization of LAAT and most likely to benefit from warfarin. Nearly half of strokes in AF are due to noncardioembolic mechanisms for which antiplatelet therapy would be more appropriate. Previous attempts to develop such tools have been limited by including patients without proven cardioembolism. Methods: Nonanticoagulated, nonvalvular AF patients with (cases) or without (controls) LAAT by transesophageal echocardiography were identified using Mayo Clinic Echocardiography and Cardioversion Unit Databases (Rochester, MN). Type and duration of AF, CHADS2 score, and echocardiography measures were compared to determine variables predictive of LAAT. Results: The CHADS2 score was significantly higher for cases (n = 110, mean ± SD 2.8 ± 1.6) compared to controls (n = 387, 1.6 ± 1.3). By multivariate analysis, independent predictors of LAAT included heart failure (HR 5.78, P < 0001), prior stroke/transient ischemic attack (HR 3.94, P < .0001), diabetes mellitus (HR 1.98, P = .015), permanent AF (HR 3.02, P < .05), AF duration (HR 2.24, P < .05), and spontaneous echocardiographic contrast (HR 4.35, P = .005). Using these elements, a new scoring system provided cleaner case-control separation (C-index 0.90) and higher predictive power compared to CHADS2 (C-index 0.71). Conclusions: The CHADS2 score predicts the presence of LAAT in AF patients. Some, but not all, variables within this score are predictive of LAAT. By including only echo and clinical variables predictive of LAAT, our novel scoring system better identified those AF patients at greatest cardioembolic risk.

Original languageEnglish (US)
Pages (from-to)665-671
Number of pages7
JournalAmerican Heart Journal
Volume159
Issue number4
DOIs
StatePublished - Apr 2010

Fingerprint

Atrial Appendage
Atrial Fibrillation
Thrombosis
Stroke
Echocardiography
Electric Countershock
Transient Ischemic Attack
Transesophageal Echocardiography
Warfarin
Diabetes Mellitus
Multivariate Analysis
Heart Failure
Databases

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Wysokinski, W. E., Ammash, N., Sobande, F., Kalsi, H., Hodge, D., & McBane, R. D. (2010). Predicting left atrial thrombi in atrial fibrillation. American Heart Journal, 159(4), 665-671. https://doi.org/10.1016/j.ahj.2009.12.043

Predicting left atrial thrombi in atrial fibrillation. / Wysokinski, Waldemar E.; Ammash, Naser; Sobande, Folakemi; Kalsi, Henna; Hodge, David; McBane, Robert D.

In: American Heart Journal, Vol. 159, No. 4, 04.2010, p. 665-671.

Research output: Contribution to journalArticle

Wysokinski, WE, Ammash, N, Sobande, F, Kalsi, H, Hodge, D & McBane, RD 2010, 'Predicting left atrial thrombi in atrial fibrillation', American Heart Journal, vol. 159, no. 4, pp. 665-671. https://doi.org/10.1016/j.ahj.2009.12.043
Wysokinski WE, Ammash N, Sobande F, Kalsi H, Hodge D, McBane RD. Predicting left atrial thrombi in atrial fibrillation. American Heart Journal. 2010 Apr;159(4):665-671. https://doi.org/10.1016/j.ahj.2009.12.043
Wysokinski, Waldemar E. ; Ammash, Naser ; Sobande, Folakemi ; Kalsi, Henna ; Hodge, David ; McBane, Robert D. / Predicting left atrial thrombi in atrial fibrillation. In: American Heart Journal. 2010 ; Vol. 159, No. 4. pp. 665-671.
@article{24e37f10315d4981b2c205be51dfee82,
title = "Predicting left atrial thrombi in atrial fibrillation",
abstract = "Background: The aim of the study was to determine whether CHADS2 score is predictive of left atrial appendage thrombus (LAAT) in nonvalvular atrial fibrillation (AF). Strategies for effective stroke prevention in AF require tools capable of identifying those patients at greatest risk for embolization of LAAT and most likely to benefit from warfarin. Nearly half of strokes in AF are due to noncardioembolic mechanisms for which antiplatelet therapy would be more appropriate. Previous attempts to develop such tools have been limited by including patients without proven cardioembolism. Methods: Nonanticoagulated, nonvalvular AF patients with (cases) or without (controls) LAAT by transesophageal echocardiography were identified using Mayo Clinic Echocardiography and Cardioversion Unit Databases (Rochester, MN). Type and duration of AF, CHADS2 score, and echocardiography measures were compared to determine variables predictive of LAAT. Results: The CHADS2 score was significantly higher for cases (n = 110, mean ± SD 2.8 ± 1.6) compared to controls (n = 387, 1.6 ± 1.3). By multivariate analysis, independent predictors of LAAT included heart failure (HR 5.78, P < 0001), prior stroke/transient ischemic attack (HR 3.94, P < .0001), diabetes mellitus (HR 1.98, P = .015), permanent AF (HR 3.02, P < .05), AF duration (HR 2.24, P < .05), and spontaneous echocardiographic contrast (HR 4.35, P = .005). Using these elements, a new scoring system provided cleaner case-control separation (C-index 0.90) and higher predictive power compared to CHADS2 (C-index 0.71). Conclusions: The CHADS2 score predicts the presence of LAAT in AF patients. Some, but not all, variables within this score are predictive of LAAT. By including only echo and clinical variables predictive of LAAT, our novel scoring system better identified those AF patients at greatest cardioembolic risk.",
author = "Wysokinski, {Waldemar E.} and Naser Ammash and Folakemi Sobande and Henna Kalsi and David Hodge and McBane, {Robert D.}",
year = "2010",
month = "4",
doi = "10.1016/j.ahj.2009.12.043",
language = "English (US)",
volume = "159",
pages = "665--671",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - Predicting left atrial thrombi in atrial fibrillation

AU - Wysokinski, Waldemar E.

AU - Ammash, Naser

AU - Sobande, Folakemi

AU - Kalsi, Henna

AU - Hodge, David

AU - McBane, Robert D.

PY - 2010/4

Y1 - 2010/4

N2 - Background: The aim of the study was to determine whether CHADS2 score is predictive of left atrial appendage thrombus (LAAT) in nonvalvular atrial fibrillation (AF). Strategies for effective stroke prevention in AF require tools capable of identifying those patients at greatest risk for embolization of LAAT and most likely to benefit from warfarin. Nearly half of strokes in AF are due to noncardioembolic mechanisms for which antiplatelet therapy would be more appropriate. Previous attempts to develop such tools have been limited by including patients without proven cardioembolism. Methods: Nonanticoagulated, nonvalvular AF patients with (cases) or without (controls) LAAT by transesophageal echocardiography were identified using Mayo Clinic Echocardiography and Cardioversion Unit Databases (Rochester, MN). Type and duration of AF, CHADS2 score, and echocardiography measures were compared to determine variables predictive of LAAT. Results: The CHADS2 score was significantly higher for cases (n = 110, mean ± SD 2.8 ± 1.6) compared to controls (n = 387, 1.6 ± 1.3). By multivariate analysis, independent predictors of LAAT included heart failure (HR 5.78, P < 0001), prior stroke/transient ischemic attack (HR 3.94, P < .0001), diabetes mellitus (HR 1.98, P = .015), permanent AF (HR 3.02, P < .05), AF duration (HR 2.24, P < .05), and spontaneous echocardiographic contrast (HR 4.35, P = .005). Using these elements, a new scoring system provided cleaner case-control separation (C-index 0.90) and higher predictive power compared to CHADS2 (C-index 0.71). Conclusions: The CHADS2 score predicts the presence of LAAT in AF patients. Some, but not all, variables within this score are predictive of LAAT. By including only echo and clinical variables predictive of LAAT, our novel scoring system better identified those AF patients at greatest cardioembolic risk.

AB - Background: The aim of the study was to determine whether CHADS2 score is predictive of left atrial appendage thrombus (LAAT) in nonvalvular atrial fibrillation (AF). Strategies for effective stroke prevention in AF require tools capable of identifying those patients at greatest risk for embolization of LAAT and most likely to benefit from warfarin. Nearly half of strokes in AF are due to noncardioembolic mechanisms for which antiplatelet therapy would be more appropriate. Previous attempts to develop such tools have been limited by including patients without proven cardioembolism. Methods: Nonanticoagulated, nonvalvular AF patients with (cases) or without (controls) LAAT by transesophageal echocardiography were identified using Mayo Clinic Echocardiography and Cardioversion Unit Databases (Rochester, MN). Type and duration of AF, CHADS2 score, and echocardiography measures were compared to determine variables predictive of LAAT. Results: The CHADS2 score was significantly higher for cases (n = 110, mean ± SD 2.8 ± 1.6) compared to controls (n = 387, 1.6 ± 1.3). By multivariate analysis, independent predictors of LAAT included heart failure (HR 5.78, P < 0001), prior stroke/transient ischemic attack (HR 3.94, P < .0001), diabetes mellitus (HR 1.98, P = .015), permanent AF (HR 3.02, P < .05), AF duration (HR 2.24, P < .05), and spontaneous echocardiographic contrast (HR 4.35, P = .005). Using these elements, a new scoring system provided cleaner case-control separation (C-index 0.90) and higher predictive power compared to CHADS2 (C-index 0.71). Conclusions: The CHADS2 score predicts the presence of LAAT in AF patients. Some, but not all, variables within this score are predictive of LAAT. By including only echo and clinical variables predictive of LAAT, our novel scoring system better identified those AF patients at greatest cardioembolic risk.

UR - http://www.scopus.com/inward/record.url?scp=77950211910&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950211910&partnerID=8YFLogxK

U2 - 10.1016/j.ahj.2009.12.043

DO - 10.1016/j.ahj.2009.12.043

M3 - Article

C2 - 20362727

AN - SCOPUS:77950211910

VL - 159

SP - 665

EP - 671

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 4

ER -